ATE210649T1 - Arylacrylamidderivate als 5ht1 agoniste oder antagoniste - Google Patents
Arylacrylamidderivate als 5ht1 agoniste oder antagonisteInfo
- Publication number
- ATE210649T1 ATE210649T1 AT97302995T AT97302995T ATE210649T1 AT E210649 T1 ATE210649 T1 AT E210649T1 AT 97302995 T AT97302995 T AT 97302995T AT 97302995 T AT97302995 T AT 97302995T AT E210649 T1 ATE210649 T1 AT E210649T1
- Authority
- AT
- Austria
- Prior art keywords
- agonists
- antagonists
- arylacrylamide
- derivatives
- arylacrylamide derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1858096P | 1996-05-28 | 1996-05-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE210649T1 true ATE210649T1 (de) | 2001-12-15 |
Family
ID=21788674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT97302995T ATE210649T1 (de) | 1996-05-28 | 1997-05-01 | Arylacrylamidderivate als 5ht1 agoniste oder antagoniste |
Country Status (9)
Country | Link |
---|---|
US (1) | US6258953B1 (de) |
EP (1) | EP0810220B1 (de) |
JP (1) | JP3026948B2 (de) |
AT (1) | ATE210649T1 (de) |
CA (1) | CA2206122C (de) |
DE (1) | DE69708968T2 (de) |
DK (1) | DK0810220T3 (de) |
ES (1) | ES2166046T3 (de) |
PT (1) | PT810220E (de) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7189753B1 (en) | 1997-11-06 | 2007-03-13 | Cady Roger K | Preemptive prophylaxis of migraine |
ATE273970T1 (de) | 1998-04-16 | 2004-09-15 | Pfizer Prod Inc | N-acyl und n-aroyl aralkylamide |
PE20000942A1 (es) * | 1998-07-31 | 2000-09-28 | Lilly Co Eli | Derivados de amida, carbamato y urea |
US6617351B1 (en) | 1998-07-31 | 2003-09-09 | Eli Lilly And Company | Amide, carbamate, and urea derivatives |
CA2448894A1 (en) * | 2001-05-31 | 2002-12-05 | Bristol-Myers Squibb Company | Cinnamide derivatives as kcnq potassium channel modulators |
US7351719B2 (en) | 2002-10-31 | 2008-04-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds |
US7045551B2 (en) | 2002-11-22 | 2006-05-16 | Bristol-Myers Squibb Company | 1-aryl-2-hydroxyethyl amides as potassium channel openers |
WO2004047744A2 (en) | 2002-11-22 | 2004-06-10 | Bristol-Myers Squibb Company | 3-heterocyclic benzylamide derivatives as potassium channel openers |
EP1572112A4 (de) | 2002-11-22 | 2006-12-06 | Bristol Myers Squibb Co | 3-(pyridinyl-piperazin-1-yl)-phenylethylamide alskaliumkanalöffner |
AU2003295782A1 (en) | 2002-11-22 | 2004-06-18 | Bristol-Myers Squibb Company | Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers |
WO2004047738A2 (en) | 2002-11-22 | 2004-06-10 | Bristol-Myers Squibb Company | Arylcyclopropylcarboxylic amides as potassium channel openers |
US7592373B2 (en) | 2003-12-23 | 2009-09-22 | Boehringer Ingelheim International Gmbh | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds |
DE10360745A1 (de) * | 2003-12-23 | 2005-07-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
US20050171095A1 (en) * | 2004-01-06 | 2005-08-04 | Pfizer Inc | Combination of CRF antagonists and 5-HT1B receptor antagonists |
JP2007537151A (ja) * | 2004-01-29 | 2007-12-20 | ファイザー・プロダクツ・インク | γ−アミノ酪酸モジュレータと5−HT1B受容体アンタゴニストとの組合せ |
WO2005107808A2 (en) * | 2004-05-11 | 2005-11-17 | Pfizer Products Inc. | Combination of atypical antipsychotics and 5-ht1b receptor antagonists |
CN102515996B (zh) * | 2011-11-14 | 2015-11-25 | 南开大学 | 一种合成β-芳基丙烯酰胺类化合物的方法 |
JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神***病を処置するための方法および組成物 |
WO2018112077A1 (en) * | 2016-12-13 | 2018-06-21 | Centaurus Therapeutics | Inhibitors of dihydroceramide desaturase for treating disease |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4564685A (en) * | 1983-03-10 | 1986-01-14 | Findlay John W A | Diphenylmethane compounds |
DK0689536T3 (da) * | 1993-03-16 | 2001-07-30 | Pfizer | Naphthalenderivater |
-
1997
- 1997-05-01 PT PT97302995T patent/PT810220E/pt unknown
- 1997-05-01 AT AT97302995T patent/ATE210649T1/de not_active IP Right Cessation
- 1997-05-01 DK DK97302995T patent/DK0810220T3/da active
- 1997-05-01 EP EP97302995A patent/EP0810220B1/de not_active Expired - Lifetime
- 1997-05-01 DE DE69708968T patent/DE69708968T2/de not_active Expired - Fee Related
- 1997-05-01 ES ES97302995T patent/ES2166046T3/es not_active Expired - Lifetime
- 1997-05-21 JP JP09130800A patent/JP3026948B2/ja not_active Expired - Fee Related
- 1997-05-26 CA CA002206122A patent/CA2206122C/en not_active Expired - Fee Related
- 1997-05-28 US US08/864,593 patent/US6258953B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ES2166046T3 (es) | 2002-04-01 |
JPH1095765A (ja) | 1998-04-14 |
DE69708968D1 (de) | 2002-01-24 |
EP0810220A1 (de) | 1997-12-03 |
EP0810220B1 (de) | 2001-12-12 |
CA2206122C (en) | 2002-03-05 |
DK0810220T3 (da) | 2002-03-18 |
PT810220E (pt) | 2002-04-29 |
JP3026948B2 (ja) | 2000-03-27 |
DE69708968T2 (de) | 2002-04-25 |
US6258953B1 (en) | 2001-07-10 |
CA2206122A1 (en) | 1997-11-28 |
MX9703899A (es) | 1998-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE210649T1 (de) | Arylacrylamidderivate als 5ht1 agoniste oder antagoniste | |
DE69628804D1 (de) | Substitutierte heterozyclische Derivate als CRF Antagonisten | |
ES2188095T3 (es) | Carboxamidas heterociclicas. | |
ID18883A (id) | Pesaing 5-ht 1f | |
ATE168992T1 (de) | 7-substituierte-9-substituierte glycylamido-6- demethyl-6-deoxytetracycline | |
ES2182234T3 (es) | Inhibidores de metaloproteasa. | |
ATE163648T1 (de) | Indole derivate als serotonin-antagonisten | |
FI920023A0 (fi) | Heteroarylpiperazinfoereningar som antipsykotiska aemnen. | |
DK1109817T3 (da) | Phosphohalogenhydriner, deres fremstilling og anvendelse | |
FI902555A0 (fi) | Diarylstyrylkinolindisyror. | |
DE60121461D1 (de) | Kondensierte pyridoindolderivate | |
ATE177096T1 (de) | 4-substituierte 1,2,4-triazolderivate | |
FI900041A0 (fi) | Substituerade indol-, benzofuran- och benzotiopenderivat saosom 5-lipoxigenasinhibitorer, | |
PT952154E (pt) | N-acil- e n-aroil-aralquilamidas | |
ID23053A (id) | Karboksamida yang digunakan sebagai agonis 5-ht <if> | |
DE60112960D1 (de) | Kondensierte pyridoindolderivate | |
ES2178765T3 (es) | Nuevos derivados de 1,7,7-trimetil-biciclo (2.2.1) heptano. | |
FI965238A0 (fi) | Aryyli- ja heteroaryylialkoksinaftaleenijohdannaiset | |
ITMI930819A1 (it) | Derivati eterobiciclici ad attivita' fungicida | |
PT1140932E (pt) | Derivados de 1,8-benzonaftiridina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification | ||
REN | Ceased due to non-payment of the annual fee |